

AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended based on the prior Examiner's amendment): A pharmaceutical composition in the form of a microemulsion preconcentrate ~~consisting essentially of~~ **comprising** a cyclosporin dissolved in a solvent system ~~consisting of~~ **including** a fully acetylated monoglyceride lipophilic solvent having a minimum acetylation of 96%, a hydrophilic organic solvent and a synergistic mixture of two **first and second** surfactants , **said first surfactant selected from, polyoxyethylene glycolated natural or hydrogenated vegetable oil, polyoxyethylene glycolated natural or hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, and a polyoxyethylene-sorbitan-fatty ester, said second surfactant selected from polyoxyethylene-sorbitan-fatty acid esters, mono- and tri-lauryl, palmityl, stearyl and oleyl esters, and polyoxyethylene 20 sorbitan monolaurate,** wherein the microemulsion preconcentrate yields a droplet size in an emulsion of less than 2000 Å as measured by light transmittance through a cell.

Claims 2 - 16 (cancelled)

Claim 17 (previously amended by Examiner's Amendment): The composition of claim 1 wherein the acetylated monoglyceride is a fully acetylated monoglyceride prepared from unsaturated monoglyceride.

Claim 18(cancelled)

Claim 19 (currently amended based on the prior Examiner's amendment) The composition of claim 1 wherein ~~said two surfactants are selected from a group consisting of one of which~~ **said surfactants** is a polyoxyethylene glycolated natural or hydrogenated vegetable oil and the second of **said surfactants** ~~which~~ is a polyoxyethylene-sorbitan-fatty acid ester.

Claim 20 (previously amended by Examiner's amendment) The composition of claim 1 wherein the hydrophilic organic solvent is miscible with the acetylated monoglyceride lipophilic solvent.

Claim 21 (previously amended by Examiner's amendment) The composition of claim 20 wherein said hydrophilic organic solvent is selected from the group consisting of ethanol,

propylene glycol, propylene carbonate, benzyl alcohol, and polyethylene glycol having mean molecular weight of less than about 1000.

Claim 22 (previously amended by Examiner's amendment) The composition of claim 1 wherein said two surfactants are selected from the group consisting of a polyoxyethylene glycolated natural, hydrogenated vegetable oil, polyoxyl 40 hydrogenated castor oil, and a polyoxyethylene-sorbitan-fatty ester.

Claim 23 (cancelled)

Claim 24 (Currently amended based on the prior Examiner's amendment) A pharmaceutical composition **in the form of a microemulsion** preconcentrate ~~consisting of~~ **comprising** cyclosporine, a fully acetylated monoglyceride having a minimum acetylation of 96%, propylene glycol, and a ~~synergistic~~ mixture of polyoxyl 40 hydrogenated castor oil and polyoxyethylene 20 sorbitan monolaurate.

Claim 25 (Currently amended based on the prior Examiner's amendment) A pharmaceutical composition **in the form of a microemulsion** preconcentrate ~~consisting of~~ **comprising** cyclosporine, a fully acetylated monoglyceride having a minimum acetylation of 96%, propylene carbonate, and a ~~synergistic~~ mixture of polyoxyl 40 hydrogenated castor oil and polyoxyethylene 20 sorbitan monolaurate.

Please add the following claims:

Claim 26 (new) A pharmaceutical composition in the form of an emulsion preconcentrate comprising cyclosporin, a fully acetylated monoglyceride having a minimum acetylation of 96% as lipophilic solvent, propylene carbonate as hydrophilic solvent, and at least one surfactant having both lipophilic and hydrophilic properties.

Claim 27 (new) The composition of claim 26 in the form of a microemulsion preconcentrate.